EBIO Eleven Biotherapeutics Reports First Quarter 2016 Financial Results: http://ih.advfn.com/p.php?pid=nmona&article=71367488 "We believe that our current cash and cash equivalents will be sufficient to fund our operating expenses into the fourth quarter of 2016"